1 Callahan MK,Wolchok JD.At the bedside:CTLA-4 and PD-1blocking antibodies in cancer immunotherapy[J].J Leukoc Biol,2013,94(1):41-53. 2 Hamid O,Carvajal RD.Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy[J].Expert Opin Biol Ther,2013,13(6):847-861. 3 Atanackovic D,Luetkens T,Kröger N.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma[J].Leukemia,2014,28(5):993-1000. 4 Murdoch C,Muthana M,Coffelt SB,et al.The role of myeloid cells in the promotion of tumour angiogenesis[J].Nature Reviews Cancer,2008,8(8):2444. 5 Yang L,Huang J,Ren X,et al.Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+myeloid cells that promote metastasis[J].Cancer Cell,2008,13(1):23-35. 6 Joyce JA,Pollard JW.Microenvironmental regulation of metastasis[J].Nature Reviews Cancer,2009,9(4):239. 7 Larkin J,Chiarion-Sileni V,Gonzalez R,et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J].N Engl J Med,2015,373(1):23-34. 8 Spodzieja M,Lach S,Iwaszkiewicz J,et al.Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses[J].PLoS One,2017,12(6):e0179201. 9 Sharma P,Wagner K,Wolchok JD,et al.Novel cancer immunotherapy agents with survival benefit:recent successes and next steps[J].Nat Rev Cancer,2011,11(11):805-812. 10 Torphy RJ,Schulick RD,Zhu Y,et al.Newly emerging immune checkpoints:promises for future cancer therapy[J].Int J Mol Sci,2017,18(12):2642. 11 张锋,韦海涛,王作培,等.食管鳞癌组织中程序性死亡分子1表达变化及意义[J].山东医药,2016,56(26):41-43. 12 Kim R,Keam B,Kwon D,et al.Programmed death ligand-1 expression and its prognostic role in esophageal squamouscell carcinoma[J].World J Gastroenterology,2016,22(37):8389-8397. 13 Zhang XF,Pan K,Weng DS,et al.Cytotoxic T lymphocyteantigen-4 expression in esophageal carcinoma:implicationsfor prognosis[J].Oncotarget,2016,7(18):26670-26679. 14 Hikita A,Tanaka N,Yamane S,et al.Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-α[J].Biochem Cell Biol,2009,87(4):581-593. 15 Kakoulidou M,Wang XB,Zhao X,et al.Soluble costimulatory factors sCD28,sCD80,sCD86 and sCD152 in relation to other markers of immune activation in patients with myasthenia gravis[J].J Neuroimmunol,2007,185(1):150-161. 16 Oaks MK,Hallett KM.Cutting edge:a soluble form of CTLA-4 in patients with autoimmune thyroid disease[J].J Immunol,2000,164(10):5015-5018. 17 Bartee MY,Dunlap KM,Bartee E.Tumor-localized secretion of soluble PD-1 enhances oncolytic virotherapy[J].Cancer Res,2017,77(11):2952-2963. 18 Liu Q,Hu P,Deng G,et al.Soluble cytotoxic T-lymphocyte antigen 4:a favorable predictor in malignant tumors after therapy[J].Onco Targets Ther,2017,10:2147-2154. 19 Lange A,Sundén-Cullberg J,Magnuson A,et al.Soluble B and T lymphocyte attenuator correlates to disease severity in sepsis and high levels are associated with an increased risk of mortality[J].PLoS One,2017,12(1):e0169176. 20 甘涛,李威,夏涛,等.腹腔镜手术与开腹结直肠癌根治术对免疫系统影响的比较[J].广东医学,2012,33(20):3125-3127. 21 Champiat S,Dercle L,Ammari S,et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J].Clin Cancer Res,2017,23(8):1920-1928. 22 Spallarossa P,Meliota G,Brunelli C,et al.Potential cardiac risk of immune-checkpoint blockade as anticancer treatment:What we know,what we do not know,and what we can do to prevent adverse effects[J].Med Res Rev,2017[Epub ahead of print]. 23 刘洋洋,谷飞飞,梁金燕,等.髓源性抑制细胞在肺癌中的研究进展[J].实用肿瘤学杂志,2016,30(3):257-261. |